product summary
Loading...
company name :
Santa Cruz Biotechnology
product type :
antibody
product name :
HoxB13 (F-9) Antibody
catalog :
sc-28333
quantity :
200 µg/ml
price :
316 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
F-9
reactivity :
human
application :
western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section, immunohistochemistry - frozen section, proximity ligation assay, western blot knockout validation
citations: 10
Published Application/Species/Sample/DilutionReference
  • western blot knockout validation; human; 1:100; loading ...; fig 3a
  • proximity ligation assay; human; 1:100; loading ...; fig 2b
VanOpstall C, Perike S, Brechka H, Gillard M, Lamperis S, Zhu B, et al. MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans. elife. 2020;9: pubmed publisher
  • immunohistochemistry - frozen section; human; 1:50; fig 1h
Kristiansen I, Stephan C, Jung K, Dietel M, Rieger A, Tolkach Y, et al. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA. Int J Mol Sci. 2017;18: pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:500; fig 3
  • western blot; human; fig 4
Pomerantz M, Li F, Takeda D, Lenci R, Chonkar A, Chabot M, et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015;47:1346-51 pubmed publisher
Lu X, Fong K, Gritsina G, Wang F, Baca S, Brea L, et al. HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. Nat Genet. 2022;54:670-683 pubmed publisher
Liu Z, Ren G, Shangguan C, Guo L, Dong Z, Li Y, et al. ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 gene. PLoS ONE. 2012;7:e40943 pubmed publisher
Ang M, Ooi A, Thike A, Tan P, Zhang Z, Dykema K, et al. Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression. Breast Cancer Res Treat. 2011;129:319-29 pubmed publisher
Jerevall P, Jansson A, Fornander T, Skoog L, Nordenskjold B, Stal O. Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Res. 2010;12:R53 pubmed publisher
Barton V, Donson A, Kleinschmidt Demasters B, Birks D, Handler M, Foreman N. Unique molecular characteristics of pediatric myxopapillary ependymoma. Brain Pathol. 2010;20:560-70 pubmed publisher
Ren G, Zhang G, Dong Z, Liu Z, Li L, Feng Y, et al. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers. Int J Biochem Cell Biol. 2009;41:1094-101 pubmed publisher
Rodriguez B, Cheng A, Yan P, Potter D, Agosto Perez F, Shapiro C, et al. Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis. 2008;29:1459-65 pubmed publisher
product information
Catalog Number :
sc-28333
Product Name :
HoxB13 (F-9) Antibody
Product Type :
Monoclonal
Host Species :
mouse
Clonality :
monoclonal
Clone Name :
F-9
Isotype :
IgG1
Size :
200 µg/ml
List Price :
316 USD
Immunogen :
HoxB13
Specificity :
human
Uses :
WB, IP, IF, IHC(P), ELISA
company information
Santa Cruz Biotechnology
2145 Delaware Avenue
Santa Cruz, CA 95060
scbt@scbt.com
https://www.scbt.com
1.800.457.3801
headquarters: USA